Telix Pharmaceuticals

Telix Pharmaceuticals

Founded as a precision oncology company, Telix Pharmaceuticals centers on theranostic radiopharmaceuticals — molecules that both diagnose and treat cancer using targeted radiation. The firm operates from a headquarters in North Melbourne, with a growing manufacturing and commercial network spanning the United States, Europe, and Asia-Pacific. Its model combines internal drug development with a vertically integrated supply chain, a structure unusual among biopharmaceutical firms at its stage. Telix deploys capital across three business units. The Therapeutics unit leads pipeline commercialization in prostate, kidney, brain, and sarcoma cancers, anchored by the Phase III ProstACT Global trial for prostate cancer therapy. The Precision Medicine unit distributes approved diagnostic agents, primarily Illuccix® for PSMA-PET imaging. The Medtech unit adds surgical tools — including the SENSEI® miniature gamma probe for robotic-assisted surgery — plus dosimetry software and AI diagnostic platforms. Confirmed commercial footprints include the United States, Australia, Canada, Belgium, Switzerland, and Japan. The firm runs a global manufacturing network under Telix Manufacturing Solutions. In 2023, it opened a radiopharmaceutical production facility in Liège, Belgium, described as one of the largest of its kind in Europe. The production capacity is designed to serve both clinical trials and commercial patient doses. Operational reach extends across nine offices on four continents, with recent expansions in Indianapolis and Angleton, Texas. Telix's architecture as a publicly traded commercial-stage biotech integrated with in-house isotope manufacturing distinguishes it from development-only radiopharmaceutical peers. The Medtech unit's combination of hardware (SENSEI®), software (dosimetry, AI), and diagnostics places the firm at the intersection of drug development and digital surgery — a configuration that pushes it beyond a standard therapeutic pipeline company into a hybrid operator model.